Newsletter Tool

Today’s Big News

Jul 7, 2025

Roche’s Chugai inks $250M Gero deal to access age-related disease targets

Jasper warns of restructuring after dud batch of urticaria drug derails trials, sinking stock

Cogent’s phase 3 hits primary endpoint, building case for filing to challenge Blueprint’s Ayvakit

Amid $15B AstraZeneca partnership rumor, Summit needs $7.7B upfront to excite investors: analyst

Apogee claims IL-13 antibody sets new eczema treatment standard in phase 2 study

4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline

KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly

53 biotech leaders urge FDA not to restrict mifepristone access over 'fatally flawed' report

Fierce Biotech's Fierce 15 nominations closing in 10 days

Featured

Roche’s Chugai inks $250M Gero deal to access age-related disease targets

By Nick Paul Taylor

Chugai Pharmaceutical has teamed up with Gero, offering up to $250 million for the chance to develop antibodies against age-related disease targets identified by its partner's AI-driven platform.

Jasper warns of restructuring after dud batch of urticaria drug derails trials, sinking stock

By James Waldron

Jasper Therapeutics is blaming a dud batch of its urticaria drug for derailing a phase 1/2 study of the candidate and raising the possibility of a restructuring to conserve cash.

Cogent’s phase 3 hits primary endpoint, building case for filing to challenge Blueprint’s Ayvakit

By Nick Paul Taylor

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval for a potential rival to Blueprint Medicines’ Ayvakit.

SAP, Answerthink Help Emerging Biopharma Firms Scale With Confidence

Amid $15B AstraZeneca partnership rumor, Summit needs $7.7B upfront to excite investors: analyst

By Angus Liu

After several PD-1xVEGF competitors forged alliances with Big Pharma players, Summit Therapeutics, the frontrunner in this hot cancer drug field, is reportedly seeking its own deal.

Apogee claims IL-13 antibody sets new eczema treatment standard in phase 2 study

By James Waldron

Apogee Therapeutics’ anti-IL-13 antibody has been tied to a 71% reduction in eczema severity after 16 weeks, hitting the main goal of a phase 2 trial.

4DMT lays off 25% of workforce while accelerating phase 3 eye gene therapy timeline

By James Waldron

4D Molecular Therapeutics laid off a quarter of its workforce last month with early-stage R&D bearing the brunt of the changes.

KalVista bounces back from FDA delay with approval for oral rare disease med Ekterly

By Fraiser Kansteiner

The FDA has approved sebetralstat under the brand name Ekterly as a new, oral treatment option for acute attacks of hereditary angioedema (HAE) in adults and children ages 12 years and older. The nod came just a few short weeks after the agency missed its June 17 target date originally established for the decision.

53 biotech leaders urge FDA not to restrict mifepristone access over 'fatally flawed' report

By Darren Incorvaia

A group of 53 biotech leaders is expressing support for mifepristone in a letter to the FDA, urging the agency not to impose new restrictions on its use as an abortion medication and slamming a "fatally flawed" report cited as reasoning for the potential limitations.

Nominations now open for Fierce Biotech's 2025 Fierce 15

By Gabrielle Masson

Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way through the industry's mercurial conditions.

Blocking an enzyme in mice restored a key protector of neurons, signaling hope for biotechs pursuing the pathway in Parkinson’s

By Darren Incorvaia

Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a new mouse study, bolstering the prospects for the biotechs currently targeting the enzyme as a treatment for Parkinson’s disease.

Trump signs big tax and spending bill into law as industry groups decry healthcare cuts

By Dave Muoio

The so-called “big, beautiful bill” fulfills several of Trump’s campaign promises to cut taxes, but will add trillions to the national debt and is opposed by the healthcare industry for cuts to funding and coverage.

Fierce podcasts

Don’t miss an episode

Teva’s CEO shares ‘Pivot to Growth’ progress

In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead.

Rethinking the mental healthcare model

AbbVie, ADCs and the future of cancer care

Resources

Whitepaper

Industry-backed, data-driven approaches to enhancing container closure integrity

This white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance.

How Will US Policy Impact the Growth of UK Biotech?

Presented by Blue Matter, strategic consultants in the life sciences

Specialized Support to Accelerate Biotech Success

Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster.